Publications by authors named "Joshua Levitsky"
Article Synopsis
- Sorafenib did not significantly improve the alveolar-arterial oxygen gradient (AaPO) in patients with hepatopulmonary syndrome (HPS) compared to a placebo after 3 months.
- Despite reducing certain angiogenic markers, such as vascular endothelial growth factor receptors, sorafenib negatively impacted mental quality of life scores, indicating potential adverse effects.
- Future research should explore different antiangiogenic therapies or approaches targeting other disease pathways for better treatment options in HPS.
The presence of preexisting (memory) or de novo donor-specific HLA antibodies (DSAs) is a known barrier to successful long-term organ transplantation. Yet, despite the fact that laboratory tools and our understanding of histocompatibility have advanced significantly in recent years, the criteria to define presence of a DSA and assign a level of risk for a given DSA vary markedly between centers. A collaborative effort between the American Society for Histocompatibility and Immunogenetics and the American Society of Transplantation provided the logistical support for generating a dedicated multidisciplinary working group, which included experts in histocompatibility as well as kidney, liver, heart, and lung transplantation.
View Article and Find Full Text PDFBackground & Aims: NS3/4A protease inhibitors, boceprevir or telaprevir, combined with peginterferon and ribavirin was the standard treatment for HCV genotype 1 and remains the only available direct antiviral drug based therapy in some countries. Efficacy and safety data in liver transplant recipients are limited.
Methods: This was a retrospective cohort study of 81 patients with genotype 1 HCV treated with boceprevir (10%) or telaprevir (90%) plus peginterferon and ribavirin at 6 US transplant centers (53% stage 3-4/4 fibrosis, 57% treatment experienced).